Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.
Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.
复制标题
DOI:
10.1038/s41598-020-73659-z
复制
发表时间:
2020-10-20
影响因子:
4.6
通讯作者:
Wu HH
中科院分区:
文献类型:
--
作者:
Tsai LH;Hsu KW;Chiang CM;Yang HJ;Liu YH;Yang SF;Peng PH;Cheng WC;Wu HH
Pancreatic cancer is the fourth leading cause of death worldwide due to its poorest prognoses with a 7% 5-year survival rate. Eighty percent of pancreatic cancer patients relapse after chemotherapy and develop early metastasis and drug resistance. Resistance to nucleoside analog gemcitabine frequently used in first-line therapy is an urgent issue in pancreatic cancer treatment. Expression of mucin (MUC) glycoproteins has been shown to enhance chemoresistance via increased cell stemness. Here we show interlukine-17 receptor B (IL-17RB) expression is positively correlated with MUC1 and MUC4 expression in pancreatic cancer cells and tumor tissue. Moreover, IL-17RB transcriptionally up-regulates expression of MUC1 and MUC4 to enhance cancer stem-like properties and resistance to gemcitabine. These results suggest IL-17RB can be a potential target for pancreatic cancer therapy. Indeed, treatment with IL-17RB-neutralizing antibody has a synergistic effect in combination with gemcitabine for killing pancreatic cancer cells. Altogether, these findings provide feasible applications for IL-17RB-targeting therapy in pancreatic cancer treatment.
登录
查看更多内容
影响因子:
8
作者:
Huang, C-K;Yang, C-Y;Lee, W-H
通讯作者:
Lee, W-H
影响因子:
2.6
作者:
Baek, Seung-Kuk;Woo, Jeong-Soo;Jung, Kwang-Yoon
通讯作者:
Jung, Kwang-Yoon
影响因子:
3.4
作者:
Saitou, M;Goto, M;Yonezawa, S
通讯作者:
Yonezawa, S
影响因子:
3.1
作者:
Hunninghake GM;Chu JH;Sharma SS;Cho MH;Himes BE;Rogers AJ;Murphy A;Carey VJ;Raby BA
通讯作者:
Raby BA
影响因子:
78.5
作者:
Kufe, Donald W.
通讯作者:
Kufe, Donald W.